<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00005952</url>
  </required_header>
  <id_info>
    <org_study_id>1735</org_study_id>
    <secondary_id>DUMC-1735-04-9R5</secondary_id>
    <secondary_id>DUMC-1735-02-9R3</secondary_id>
    <secondary_id>DUMC-1735-01-9R2</secondary_id>
    <secondary_id>DUMC-1833-99-10</secondary_id>
    <secondary_id>NCI-G00-1796</secondary_id>
    <secondary_id>CDR0000067932</secondary_id>
    <nct_id>NCT00005952</nct_id>
  </id_info>
  <brief_title>Temozolomide Plus Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Malignant Glioma or Recurrent CNS or Other Solid Tumors</brief_title>
  <official_title>A Phase I/II Trial of Temodar in Pediatric Patients and Young Adults With High-Risk or Recurrent Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation&#xD;
      may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase I/II trial is studying the side effects and best dose of temozolomide&#xD;
      when given with peripheral stem cell transplantation and to see how well they work in&#xD;
      treating children with newly diagnosed malignant glioma or recurrent CNS tumors or other&#xD;
      solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the maximum tolerated dose of temozolomide in children with newly diagnosed&#xD;
           malignant glioma or recurrent CNS or other solid tumors.&#xD;
&#xD;
        -  Evaluate the toxicity of this treatment in these patients.&#xD;
&#xD;
        -  Determine the activity of this treatment in these patients.&#xD;
&#xD;
      OUTLINE: This is a dose escalation study of temozolomide.&#xD;
&#xD;
      Patients receive filgrastim (G-CSF) subcutaneously (SQ) or IV beginning on day -5 and&#xD;
      continuing through at least day 3. Peripheral blood stem cells (PBSC) are collected on days&#xD;
      0, 2, and 4. Patients then receive oral temozolomide daily for 5 consecutive days. PBSC&#xD;
      collections are reinfused 1 day after the last dose of temozolomide. Patients also receive&#xD;
      G-CSF beginning at the time of transplant and continuing until blood counts recover.&#xD;
      Treatment continues in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of temozolomide until the maximum tolerated&#xD;
      dose (MTD) is determined. The MTD is defined as the dose at which 2 of 6 patients experience&#xD;
      dose limiting toxicities.&#xD;
&#xD;
      Patients are followed every 3 months for 1-3 years, then annually thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study over 12 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2000</start_date>
  <completion_date type="Actual">November 2005</completion_date>
  <primary_completion_date type="Actual">November 2005</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Overall response at 12 months</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Disease-free survival at 12 months</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity by NCI Common Toxicity Criteria v. 3.0 at 12 months</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Engraftment related to autologous marrow or peripheral blood stem cell transplantation at 12 months</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Brain and Central Nervous System Tumors</condition>
  <condition>Childhood Germ Cell Tumor</condition>
  <condition>Head and Neck Cancer</condition>
  <condition>Kidney Cancer</condition>
  <condition>Neuroblastoma</condition>
  <condition>Ovarian Cancer</condition>
  <condition>Sarcoma</condition>
  <condition>Testicular Germ Cell Tumor</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>temozolomide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplantation</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed newly diagnosed malignant glioma or recurrent malignant CNS&#xD;
             tumor of any pathology OR&#xD;
&#xD;
          -  Histologically confirmed non-CNS tumor&#xD;
&#xD;
               -  Recurrent soft tissue sarcomas (e.g., rhabdomyosarcoma)&#xD;
&#xD;
               -  Recurrent or resistant neuroblastoma&#xD;
&#xD;
               -  Recurrent Wilm's tumor&#xD;
&#xD;
               -  Recurrent Ewing's sarcoma&#xD;
&#xD;
               -  Recurrent primitive neuroectodermal tumors&#xD;
&#xD;
               -  Recurrent nasopharyngeal carcinoma&#xD;
&#xD;
               -  Recurrent germ cell tumor&#xD;
&#xD;
          -  Expected cure rate less than 10% with standard therapy&#xD;
&#xD;
          -  Measurable and/or active disease&#xD;
&#xD;
          -  History of bone marrow tumor infiltration with or without mass lesions or isolated&#xD;
             abnormal CSF cytology as only evidence of recurrent disease allowed if complete&#xD;
             response was first achieved with primary conventional therapy&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and under&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Karnofsky 70-100% OR&#xD;
&#xD;
          -  Lansky 70-100%&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Greater than 8 weeks&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Reasonably cellular bone marrow (greater than 15% cellularity on biopsy)&#xD;
&#xD;
          -  Absolute neutrophil count greater than 1,000/mm^3&#xD;
&#xD;
          -  Platelet count greater than 75,000/mm^3&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin less than 2.0 mg/dL&#xD;
&#xD;
          -  SGPT less than 120 U/L&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine less than 1.5 mg/dL&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  Systolic fraction or ejection fraction at least 80% predicted for age by&#xD;
             echocardiogram&#xD;
&#xD;
        Pulmonary:&#xD;
&#xD;
          -  CVC or DLCO at least 60% predicted for age OR clearance from pulmonologist&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No active infection&#xD;
&#xD;
          -  Able to tolerate vigorous hydration schedule&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  No concurrent white blood cell transfusion&#xD;
&#xD;
          -  No other concurrent hematopoietic growth factors&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 4 weeks since prior chemotherapy&#xD;
&#xD;
          -  No other concurrent cytotoxic drugs (systemic or intrathecal)&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Concurrent corticosteroids allowed&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 1 week since prior radiotherapy&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  At least 1 week since prior surgery&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Henry S. Friedman, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Duke Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Duke Comprehensive Cancer Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <study_first_submitted>July 5, 2000</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>June 19, 2013</last_update_submitted>
  <last_update_submitted_qc>June 19, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 20, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>childhood low-grade cerebral astrocytoma</keyword>
  <keyword>recurrent childhood rhabdomyosarcoma</keyword>
  <keyword>childhood craniopharyngioma</keyword>
  <keyword>disseminated neuroblastoma</keyword>
  <keyword>stage 4S neuroblastoma</keyword>
  <keyword>recurrent neuroblastoma</keyword>
  <keyword>stage IV Wilms tumor</keyword>
  <keyword>stage V Wilms tumor</keyword>
  <keyword>recurrent Wilms tumor and other childhood kidney tumors</keyword>
  <keyword>childhood central nervous system germ cell tumor</keyword>
  <keyword>stage III malignant testicular germ cell tumor</keyword>
  <keyword>recurrent malignant testicular germ cell tumor</keyword>
  <keyword>stage IV nasopharyngeal cancer</keyword>
  <keyword>recurrent nasopharyngeal cancer</keyword>
  <keyword>childhood germ cell tumor</keyword>
  <keyword>metastatic childhood soft tissue sarcoma</keyword>
  <keyword>recurrent childhood soft tissue sarcoma</keyword>
  <keyword>stage IV ovarian germ cell tumor</keyword>
  <keyword>recurrent ovarian germ cell tumor</keyword>
  <keyword>childhood high-grade cerebral astrocytoma</keyword>
  <keyword>childhood oligodendroglioma</keyword>
  <keyword>childhood choroid plexus tumor</keyword>
  <keyword>untreated childhood brain stem glioma</keyword>
  <keyword>recurrent childhood brain stem glioma</keyword>
  <keyword>untreated childhood supratentorial primitive neuroectodermal tumor</keyword>
  <keyword>recurrent childhood supratentorial primitive neuroectodermal tumor</keyword>
  <keyword>untreated childhood cerebellar astrocytoma</keyword>
  <keyword>recurrent childhood cerebellar astrocytoma</keyword>
  <keyword>recurrent childhood cerebral astrocytoma</keyword>
  <keyword>untreated childhood medulloblastoma</keyword>
  <keyword>recurrent childhood medulloblastoma</keyword>
  <keyword>untreated childhood visual pathway and hypothalamic glioma</keyword>
  <keyword>recurrent childhood visual pathway and hypothalamic glioma</keyword>
  <keyword>previously treated childhood rhabdomyosarcoma</keyword>
  <keyword>metastatic Ewing sarcoma/peripheral primitive neuroectodermal tumor</keyword>
  <keyword>recurrent Ewing sarcoma/peripheral primitive neuroectodermal tumor</keyword>
  <keyword>newly diagnosed childhood ependymoma</keyword>
  <keyword>recurrent childhood ependymoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Neuroblastoma</mesh_term>
    <mesh_term>Neoplasms, Germ Cell and Embryonal</mesh_term>
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Temozolomide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

